A second SAE, a bladder transitional cell carcinoma diagnosed in week 80 during somapacitan treatment in the daily GH/somapacitan group, was assessed as possibly related to both daily GH and somapacitan. Here, GH1 is linked to bladder transitional cell carcinoma.